Germany’s Merck KGaA has agreed to acquire UK-based Silence Therapeutics in an all-cash transaction valuing the biotechnology company’s equity at approximately $1.3 billion.
Merck will pay $20 for each Silence American depositary share, more than double the company’s closing price before the transaction was announced.
The acquisition centers on Silence’s short-interfering RNA technology and its lead experimental drug, divesiran.
Divesiran is being developed for polycythemia vera, a rare blood cancer characterized by excessive production of red blood cells. The experimental treatment is ready to enter late-stage clinical development.
The transaction expands Merck’s effort to build a more specialized pharmaceutical pipeline following its acquisition of SpringWorks Therapeutics last year.
For Merck, the acquisition provides another potential late-stage medicine while expanding its capabilities in gene-silencing technology.
The deal remains subject to required shareholder and regulatory approvals.
For investors, the central question is whether divesiran’s encouraging earlier clinical development translates successfully into late-stage trials and ultimately regulatory approval.
The transaction gives Merck a potentially valuable rare-disease asset, but its eventual commercial value remains dependent on clinical and regulatory outcomes that have not yet been established.
